Cargando…
Combination of Peptide YY(3–36) with GLP-1(7–36 amide) Causes an Increase in First-Phase Insulin Secretion after IV Glucose
CONTEXT: The combination of peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) has been proposed as a potential treatment for diabetes and obesity. However, the combined effects of these hormones, PYY(3–36) and GLP-1(7–36 amide), on glucose homeostasis are unknown. OBJECTIVE: This study sought to...
Autores principales: | Tan, Tricia M., Salem, Victoria, Troke, Rachel C., Alsafi, Ali, Field, Benjamin C. T., De Silva, Akila, Misra, Shivani, Baynes, Kevin C. R., Donaldson, Mandy, Minnion, James, Ghatei, Mohammad A., Godsland, Ian F., Bloom, Stephen R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4258604/ https://www.ncbi.nlm.nih.gov/pubmed/25144632 http://dx.doi.org/10.1210/jc.2014-2143 |
Ejemplares similares
-
The Gut Hormones PYY(3-36) and GLP-1(7-36 amide) Reduce Food Intake and Modulate Brain Activity in Appetite Centers in Humans
por: De Silva, Akila, et al.
Publicado: (2011) -
Preparedness of healthcare workers at French Ebola referral centres
por: Tarantini, C., et al.
Publicado: (2015) -
Gender-based differences in COVID-19
por: Su, Y.-J., et al.
Publicado: (2021) -
SARS-CoV-2 & Rheuma: Konsequenzen der SARS-CoV-2-Pandemie für Patienten mit entzündlich rheumatischen Erkrankungen. Ein Vergleich der Handlungsempfehlungen rheumatologischer Fachgesellschaften und Risikobewertung verschiedener antirheumatischer Therapien
por: Leipe, J., et al.
Publicado: (2020) -
Impfung gegen SARS-CoV-2 bei entzündlich rheumatischen Erkrankungen: Empfehlungen der DGRh für Ärzte und Patienten
por: Specker, C., et al.
Publicado: (2021)